Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;459(4):361-6.
doi: 10.1007/s00428-011-1140-8. Epub 2011 Aug 28.

Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma

Affiliations

Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma

Mona A A Zaki et al. Virchows Arch. 2011 Oct.

Abstract

To evaluate roles of tumor-associated macrophages (TAMs) for prognosis of classical Hodgkin lymphoma (CHL). Expression of markers for TAMs, CD68, HLA-DR, CD163, HLA-DR/CD68 (M1), and CD163/CD68 (M2) was immunohistochemically examined in 82 cases with CHL. Positively stained cells were counted and correlation of number of TAMs and patients' survival time was analyzed. Number of CD163+ cells and M2 cells was significantly correlated with shorter overall survival (P < 0.05), while it was marginally significant for CD68+ cells (P = 0.0827). HLA-DR + cells and M1 cells showed no significant correlation with overall survival. When confined to mixed cellularity subtype, number of M1 cells was correlated with favorable prognosis (P < 0.05), while M2 did not (P = 0.7). Older age and male sex were unfavorable factors for prognosis. At multivariate analysis, number of CD163+ cells, M2+ cells, and age were independent factors for poor overall survival (P = 0.03, 0.02, and 0.01, respectively). CD163+ cells and M2 cells might work to be tumor promotive in CHL. M1 cells might be tumor suppressive in mixed cellularity type.

PubMed Disclaimer

References

    1. Eur J Cancer Clin Oncol. 1986 Sep;22(9):1117-9 - PubMed
    1. J Invest Dermatol. 2009 Apr;129(4):1016-25 - PubMed
    1. J Exp Med. 1996 Aug 1;184(2):695-706 - PubMed
    1. J Clin Oncol. 2009 Jul 10;27(20):3330-7 - PubMed
    1. Clin Cancer Res. 2011 Apr 15;17(8):2110-9 - PubMed

Publication types

LinkOut - more resources